METASTASIS AND ADAPTIVE RESISTANCE INHIBITING IMMUNOTHERAPY COMBINED ONLINECHEMOTHERAPY (43)Pub.Date: Dec.13,2018 WITH RADIOTHERAPY’STUMOR SEEKING EXTRACELLULAR VESICLESWITH SIRNA AND CHEMOTHERAPEUTICS

Sahadevan, Velayudhan. "Metastasis and Adaptive Resistance Inhibiting Immunotherapy Combined Online Chemotherapy with Radiotherapy's tumor Seeking Extracellular Vesicles with siRNA and Chemotherapeutics." U.S. Patent Application 15/621,973, filed December 13, 2018.

Abstract
Mutated genome silencing with endogenous RNAi-siRNA and miRNA with near total cellular apheresis with pulse flow apheresis system and EV-exosome-RNA molecular apheresis with sucrose density gradient continuous flow ultracentrifugation combined with array centrifuge for both 50S higher and 50S lower proteomics and genomics apheresis and their fractionated purification with immobilized Tim4-Fc protein Ca2+ magnetic beads affinity chromatography (ACG) and immobilized metal ACG is disclosed. It purifies normal cell derived and tumor cell derived EVs-exosomes, proteomics and subcellular particles. Tumor-specific endogenous siRNA is generated from mutated RNA containing pre-miRNA hairpin through RNA-induced silencing complex (RISC) composed of Dicer, dsRNA binding protein TRBP, and AGO2. Incubating purified RSIC with pre-let-7 hairpin generates siRNA. SiRNA is bonded with T-EVs and T-cells to silence its evasion from tumor immunity. While on radiation therapy or surgery, a patient’s blood is continuously processed with above systems. It delivers combined online radiotherapy, and tumor-seeking adoptive extracorporeal chemo-immunotherapy.

View full article